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Breast cancer is the second most common cancer worldwide, accounting for 25% of all female cancers. Although the survival rate has increased significantly in the past few decades, patients who develop secondary site metastasis as well as those diagnosed with triple negative breast cancer still represent a real unmet medical challenge. Previous studies have shown that chloropyramine (C4) inhibits FAK-VEGFR3 signalling. More recently, C4 is reported to have SASH1 inducing properties. However, C4 exerts its antitumour and antiangiogenic effects at high micromolar concentrations (>100 μm) that would not be compatible with further drug development against invasive breast cancer driven by FAK signalling. In this study, molecular modelling guided structural modifications have been introduced to the chloropyramine C4 scaffold to improve its activity in breast cancer cell lines. Seventeen compounds were designed and synthesized, and their antiproliferative activity was evaluated against three human breast cancer lines (MDA-MB-231, BT474 and T47D). Compound 5c was identified to display an average activity of IC 50 = 23.5-31.3 μm, which represents a significant improvement of C4 activity in the same assay model. Molecular modelling and pharmacokinetic studies provided more promising insights into the mechanistic features of this new series.
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| INTRODUCTION
Current therapeutic strategies for breast cancer (BC) are mainly directed towards primary tumour site histopathology, that is expression of oestrogen (ER), progesterone (PR) and human epidermal growth factor 2 (HER2) receptors. Due to improved therapeutic strategies, the survival rate for ERpositive breast cancer in particular has increased significantly in the past few decades. However, the subgroup of aggressive and invasive breast cancers, including triple-negative disease (around 15% of cases), is characterized by rapid relapse following chemotherapy and progression to metastatic disease, with a poor overall prognosis. 1 Focal adhesion kinase (FAK) is a cytoplasmic tyrosine kinase and scaffold protein, which is localized to focal adhesions, and forms points of contacts between cells and the extracellular matrix. FAK is highly expressed in cancer, acts as a multifunctional mediator of cell signalling, and its involvement in cancer cell proliferation, invasion and metastasis is well documented. [1] [2] [3] [4] [5] [6] It is overexpressed in many types of cancer such as thyroid, brain, liver, prostate, breast, colon, head and neck. Moreover, this overexpression is associated with an invasive phenotype in such tumours. [6] Numerous approaches are being developed to inhibit FAK catalytic function (mainly targeting the Y397 tyrosine phosphorylation site), which have successfully led to the development of clinical stage FAK kinase inhibitors such as defactinib, currently in Phase I/II trials in ovarian, non-small cell lung, mesothelioma and pancreatic cancer (Verastem, Inc.) [7] Alternatively, destabilization of the FAK scaffolding function is believed to be an advantageous and potentially more specific strategy to develop FAK targeting therapeutics rather than focusing on the kinase function only. [6] [7] [8] [9] [10] In silico screening of the National Cancer Institute's small molecule library for compounds targeting the FAK-VEGFR3 interactions led to the identification of the clinically approved drug chloropyramine (C4) which belongs to the first generation of H1-antihistamines. [11, 12] Further in vitro and in vivo studies have
shown that treatment with C4 showed reduction in tumour burden and neovascularization in mouse models of breast cancer. [11] This activity has been demonstrated, both alone and synergistically with other chemotherapeutic agents (e.g., doxorubicin and gemcitabine), sensitizing breast cancer cells to chemotherapy. [11, 12] Moreover, C4 is under development by CureFAKtor Pharmaceuticals LLC, and received orphan drug designation from the FDA in combination with gemcitabine for the treatment of pancreatic cancer. [13] More recently, Burgess et al. have independently used in silico connectivity mapping and in vitro modelling to demonstrate that chloropyramine C4, increased SASH1 protein levels in breast cancer cells. [14] Expression of the SASH1 protein is reduced in a range of human cancers and has been implicated in apoptotic cancer cell death. Although C4 is an attractive candidate, it exerts its antitumour and antiangiogenic effects at high micromolar concentrations (>100 μm). [12] In order to get more insights into the structure activity relationships (SAR) and improve the antitumour potency of C4, we introduced new chemical motifs into the scaffold of C4. These modifications were tested in a preliminary in silico study that suggested an improved interaction with the FAK-FAT domain. The newly designed compounds were synthesized and screened in vitro against three human breast cancer cell lines (MDA-MB-231, BT474 and T47D). Our findings show that compound 5c, which displayed the best antiproliferative potency amongst all tested analogues, is a novel compound that warrants further investigation as a candidate for breast cancer therapy.
| METHODS AND MATERIALS

| Lead optimization and design of novel chloropyramine (C4) analogues
Based on the previous promising findings with chloropyramine (C4), [11, 12] we sought to improve upon the chemical structure of C4 to understand better its structure activity relationship (SAR) and to improve its antiproliferative potency (C4 IC 50 >100 μm). To investigate the impact of various substituents of C4 on the antitumour efficacy, a series of novel derivatives were designed and prepared, as detailed in Figure 1 , and Schemes 1 and 2. Structural modifications involved replacing the pyridine moiety with other aromatic systems containing a carboxylate moiety to enhance the interaction with Lys 1032 within the FAK-FAT domain, introducing an extended carbon atom moiety (region A, Figure 1 ) or introducing a carbonyl group into N,N-dimethylamino ethyl side chain (region C, Figure 1 ). The p-chlorobenzyl group (region B, Figure 1 ) was retained unmodified in most compounds as it is involved in key interactions via a π-π stacking with the aromatic side chain of Tyr 925. The salicylate aromatic moiety replacing the pyridine ring was reported to mimic the phosphorylated tyrosine (pTyr). [15, 16] Molecular modelling studies of the newly designed compounds showed improved binding interaction modes within the FAK-FAT pocket compared to the parent C4 compound due to a better orientation effect on the side chain (region C, Figure 1 ). All the prepared compounds were evaluated against three breast cancer lines, that is MDA-MB-231 (TNBC), BT474 (ER + , HER + ) and T47D (ER + , HER − ).
| Chemical synthesis
The first series of compounds containing an extended carbon unit in the C4 skeleton (5a-d, region A modification) were synthesized as shown in Scheme 1. The in good yields. [17] It is worth mentioning that the reaction conditions of this step were optimized in terms of solvent and temperature choice for the different aldehydes used (see Section 2). These intermediates were alkylated with p-chlorobenzyl chloride 4 to give the target analogues (5a-d) in good to moderate yield (57%-69%). Interestingly, in the case of 4-((2-(dimethylamino)ethylamino)methyl) benzonitrile 3a, a quaternary ammonium side product 6 was obtained alongside the expected product 5a (in 1:3 ratio, respectively). Unexpectedly, in the case of 2-cyanobenzaldehyde 7, the cyclized isoindolinone derivative 8 was isolated instead of the desired Schiff's base, Scheme 2A. A plausible mechanism is suggested where the initial step is the nucleophilic addition of the amine 2 to the formyl group of 7 affording the adduct 7a, which subsequently cyclizes to 7b by intramolecular nucleophilic addition of the hydroxyl group to the cyano group of 7a, followed by conversion to the isoindolinone derivative 8, Scheme 2B. [18] The second series of compounds (13a-m), featuring an additional carbonyl group in the N,N-dimethylamino ethyl side chain moiety of C4, were prepared according to Scheme 3A. The first step involved a reductive amination reaction [19] between the corresponding aniline derivative (9a-l) and p-halobenzaldehyde (10a or 10b) to give the key intermediates (11a-l). The final compounds were obtained by reacting N,N-dimethylaminoacetyl chloride hydrochloride 12 with intermediates (11a-l) in tetrahydrofuran at room temperature. The reductive amination of 5-amino-2-hydroxybenzoic acid with p-chlorobenzaldehyde (10a) was not feasible due to the instability of the intermediate product (11m). For this reason, we managed to get the corresponding target product 13m via the hydrolysis of 13c using NaOH solution in a very good yield (92%), Scheme 3A. Interestingly, double reductive amination occurred in the case of compound 9m to give 14 which was hydrolysed to 15 using NaOH. The structures of all the synthesized compounds were confirmed using analytical and spectroscopic data (NMR, mass spectrometry), which were in full accordance with their depicted structure. All final compounds were purified and tested as free bases.
S C H E M E 3 (A) Synthesis of compounds (13a-m). Reagents and conditions: (a) MeOH
| RESULTS AND DISCUSSION
| Cell viability assay
The antiproliferative activity of all the synthesized com- . Chloropyramine C4 was used as a control drug. The corresponding cell lines were seeded the day before incubation, and then incubated for 72 hr with the different concentrations of compound tested. CellTiter Glo reagent (25 μl) was added to the cell plate. The luminescence was recorded after 10 min on a PerkinElmer Envision instrument. All the twenty-one compounds were tested at 10 concentrations in half log increments up to 100 μm in triplicate. The results indicated that three compounds (5c, 6 and 15) have better antiproliferative activity than chloropyramine C4, which did not show any antiproliferative activity up to 100 μm concentration across the three BC cell lines. The most active compound 5c showed micromolar activity across the three BC cell lines; (MDA-MB-231, IC 50 = 23.5 μm), (BT474, IC 50 = 73.2 μm) and (T47D, IC 50 = 31.3 μm), Figure 2a . Interestingly, the quaternary ammonium compound 6 and the double reductive amination product 15, displayed better antiproliferative activity than C4, Figure 2b ,c, respectively. All the other tested analogues showed no observed improvement in the antiproliferative activity over the parent compound C4 (all compounds were tested at maximum concentration of 100 μm).
| Molecular modelling
In silico docking was performed on all the designed analogues using the downloaded crystal structure of FAK (PDB ID: 1K05). [20] The chemical structures of the compounds were constructed, rendered and minimized with the MMFF94x force field in MOE. Docking simulations were performed using Glide SP in Maestro (Glide, version 9.5, Schrödinger, LLC, New York, NY. http://www. schrodinger.com). Based on the surface representation of the FAK-FAT domain, there appears to be an improved interaction over the parent C4 upon the introduction of an extended carbon linker, compounds (5a-d), or introduction of a carbonyl group as in compounds (13a-m) into the general chloropyramine scaffold. Figure 3a shows the predicted docking mode of the most active compound 5c compared to that of the parent compound (Figure 3a) . The relatively higher activity of compound 5c appears to be a result of the better directing effect of the N,N-dimethylamino side chain conferred by the extra carbon moiety. On the other hand, according to our model, the introduction of the carbonyl group into the N,N-dimethylamino ethyl moiety of C4 (e.g., 13a) showed an improved effect on orienting the N,Ndimethylamino ethyl group into the polar pocket around Asp 1036 as well as directing the other aromatic group to the hydrophobic pocket, Figure 3b . However, none of the carbonyl containing compounds (13a-m) were able to demonstrate any better antiproliferative activity than C4, probably because of the reduced basicity of the N,N-dimethylamino moiety upon the introduction of the carbonyl group. Generally, our study of the two modified series of compounds suggests that more substantial structural modifications of C4 are needed to significantly improve the antiproliferative activity in BC cell lines.
| In vitro aqueous solubility and microsomal metabolic stability
Subsequently, in vitro pharmacokinetic studies of the most active compound 5c were performed. The in vitro aqueous solubility was investigated using five concentrations of 5c, that is (1, 3, 10, 30 and 100 μm), which were incubated at 37°C for 2 hr. The estimated precipitation range (lower and upper bound) and a mid-range value were calculated for 5c. Nicardipine and pyrene are included as control compounds. The results show that compound 5c has a very good aqueous solubility with estimated precipitation range 100 μm (lower bound) and >100 μm (upper bound), Table 1 . This relatively high aqueous solubility could prove to be a possible solution to the sedation side-effect of chloropyramine because of its ability to cross the blood brain barrier (BBB). [14] The calculated logP values (C4 = 3.99, 5c = 4.42) are similar but tPSA values (C4 = 18.84, 5c = 32.78) suggest that 5c is less likely to cross the BBB. Furthermore, the metabolic stability of 5c was tested in human liver microsomes. Compound 5c was incubated for 45 min with pooled liver microsomes and the intrinsic clearance (CL int ) and half-life (t 1/2 ) values were calculated based on 5 time-points. The values of intrinsic clearance (CL int ) as well as half-life values of 5c compared to control compounds, dextromethorphan and verapamil, are shown in Table 2 . Compound 5c has microsomal half-life (t 1/2 ) of 59.4 min, which exceeds that of the registered drug controls dextromethorphan (t 1/2 = 48.2 min) and verapamil (t 1/2 = 8.0 min), and represents a good starting point for optimization towards a daily administrable product.
| CONCLUSION
In this study, two series of novel chloropyramine C4 analogues were designed and synthesized. The antiproliferative activity of compounds (5a-d) and (13a-m) was evaluated as free bases in vitro across three human breast cancer cell lines; MDA-MB-231 (TNBC), BT474 (ER + , HER + ) and T47D
(ER + , HER − ). The results identified compound 5c as having the most significant antiproliferative activity, displaying micromolar activity across the three breast cancer cell lines; (MDA-MB-231, IC 50 = 23.5 μm), (BT474, IC 50 = 73.2 μm) and (T47D, IC 50 = 31.3 μm). This activity represents a significant improvement to the chloropyramine C4, which did not display any antiproliferative activity up to 100 μm. Further pharmacokinetic study showed that 5c performed well in both the aqueous solubility and microsomal metabolic stability analysis. Considering the above findings, it could be concluded that 5c represents a promising basis for further development of breast cancer therapeutics targeting the FAK scaffolding domain.
